The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...

News provided by Helius Medical Technologies, Inc. Jun 16, 2025, 7:00 AM ET - CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS ...

The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...

The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an ...

Helius Medical (HSDT) Technologies announced its first reimbursement payment from a major healthcare provider, Anthem Blue Cross Blue Shield, for its Portable Neuromodulation Stimulator, PoNS ...

The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an ...

The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from ...

News provided by Helius Medical Technologies, Inc. Jun 11, 2025, 7:00 AM ET -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join ...